Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLRMT | O00411 | 1/20 | 0.38 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16710454 | 0.82 | PI4KA (0.47) | POLRMTDOT1LSTING1MAP4K4PI4KA | |
| SCHEMBL13532207 | 0.82 | PI4KA (0.47) | POLRMTDOT1LSTING1MAP4K4PI4KA | |
| SCHEMBL15605903 | 0.81 | POLRMT (0.37) | POLRMTDOT1LSTING1MAP4K4PI4KA | |
| SCHEMBL16708543 | 0.81 | POLRMT (0.37) | POLRMTDOT1LSTING1MAP4K4PI4KA | |
| SCHEMBL19344228 | 0.80 | POLRMT (0.37) | POLRMTDOT1LSTING1MAP4K4PI4KA | |
| SCHEMBL26829967 | 0.78 | POLRMT (0.37) | POLRMTDOT1LSTING1PI4KAPI4K2B | |
| SCHEMBL24606260 | 0.77 | POLRMT (0.37) | POLRMTDOT1LSTING1PI4KAPI4K2B | |
| SCHEMBL26829262 | 0.77 | POLRMT (0.36) | POLRMTDOT1LSTING1RIPK1PI4KA | |
| SCHEMBL15606981 | 0.76 | ADORA3 (0.42) | — | |
| SCHEMBL15605853 | 0.76 | POLRMT (0.34) | POLRMTDOT1LRIPK1PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426664-B1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-30 | — | — | EP | disclosed |
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
| WO-2017153186-A1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | POLRMT 407/4885DOT1L 23/4885STING1 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.